SCHEMBL4189849

SCHEMBL4189849

CCCN(CCC)S(=O)(=O)c1ccc(NC(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 12/20 0.68
CA12 O43570 11/20 0.68
CA1 P00915 6/20 0.68
CA2 P00918 3/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
RAB9A P51151 1/20 0.65
SLC22A6 Q4U2R8 1/20 0.65
SLC22A8 Q8TCC7 1/20 0.65
ABCC2 Q92887 1/20 0.65
SLC22A12 Q96S37 1/20 0.65
UGT1A7 Q9HAW7 1/20 0.65
SLC22A11 Q9NSA0 1/20 0.65
MAPT P10636 4/20 0.64
POLB P06746 3/20 0.64
NPSR1 Q6W5P4 2/20 0.64
GAA P10253 1/20 0.64
ABCC9 O60706 1/20 0.64
ABCC8 Q09428 1/20 0.64
KCNJ11 Q14654 1/20 0.64
KCNJ8 Q15842 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176762 0.87 KMT2A (0.62) SMN1; SMN2RAB9AMAPTPOLBNPSR1
SCHEMBL17947763 0.84 CA9 (0.90) CA9CA12CA1CA2SMN1; SMN2
SCHEMBL12585053 0.83 CA9 (0.79) CA9CA12CA1CA2SMN1; SMN2
SCHEMBL10119209 0.82 MAPT (0.67) CA9CA12CA1CA2SMN1; SMN2
SCHEMBL16615487 0.82 MAPT (0.69) CA9CA12CA1CA2MAPT
SCHEMBL16615501 0.80 CA1 (0.67) CA9CA12CA1CA2SMN1; SMN2
SCHEMBL6312180 0.80 ABCC9 (0.62) CA9CA12CA1CA2SMN1; SMN2
SCHEMBL16615520 0.80 MAPT (0.66) CA9CA12CA1RAB9AMAPT
SCHEMBL16615819 0.79 LMNA (0.64) CA9CA12CA1SMN1; SMN2RAB9A
SCHEMBL16615503 0.79 CA12 (0.61) CA9CA12CA1CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 US claimed
WO-2007005887-A2 ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-01-11 WO claimed
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 US disclosed
WO-2007005887-A2 ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA CA9 2903/4885CA12 3565/4885CA1 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.